Findings {#Sec1}
========

Background {#Sec2}
----------

Working memory, the ability to retain information for a short period of time \[[@CR1]\], is regarded as a core cognitive function that underpins a wide range of complex behaviours such as problem solving, decision-making and reasoning. A substantial number of neuroimaging studies using fMRI have shown that the dorsolateral prefrontal cortex (DLPFC) is the key cortical region involved in working memory \[[@CR2]\]. Moreover, several neurotransmitters are known to be involved in this process.

Among the multiple neurotransmitter systems, components of histaminergic neurotransmission, particularly H~3~ receptors, are known to modulate working memory in animals \[[@CR3]\]. The H~3~ receptor is a presynaptic receptor that regulates the release of histamine (as an autoreceptor) as well as other neurotransmitters such as dopamine, norepinephrine and acetylcholine (as a heteroreceptor), which are involved in cognitive function \[[@CR3]\]. More specifically, increased release of histamine via H~3~ receptor antagonists has been shown to improve working memory in rats under various maze tasks and the delayed match-to-sample test \[[@CR3]\]. Thus, extensive preclinical studies have assessed the role of H~3~ receptors in working memory. However, very few such studies have been conducted in humans, and the published clinical studies of H~3~ receptor antagonist/inverse agonists have shown the mixed results of cognitive improvements in neuropsychiatric diseases (\[[@CR4], [@CR5]\] for review). For example, some studies reported the positive effects of H~3~ receptor drugs in episodic memory in Alzheimer's disease, while others found no beneficial effects examined by various drugs in different diseases \[[@CR5]\]. These unclear therapeutic effects may come from the complex biology and pharmacology of H~3~ receptor, such as the heterogeneity of isoforms and the different profile of drug activity (full agonists, partial agonists, neutral antagonists, inverse agonists and protean ligands) \[[@CR5]\].

Nevertheless, H~3~ receptors are highly expressed in the human cerebral cortex and basal ganglia, as revealed by autoradiographic studies of post-mortem brain tissue and by recent PET studies using radioligands targeting H~3~ receptors \[[@CR3], [@CR6]\]. Furthermore, a post-mortem brain sample study revealed that the prefrontal cortex of schizophrenia patients with cognitive impairments showed increased H~3~ receptor binding \[[@CR7]\].

Thus, because the prefrontal cortex is the key region for working memory and H~3~ receptors are highly expressed in this region, the present study aimed to clarify whether brain activity related to working memory was associated with H~3~ receptor density in the prefrontal cortex. To accomplish this, we used fMRI as well as PET with the radioligand \[^11^C\] TASP457, which has high affinity and selectivity for H~3~ receptors \[[@CR6], [@CR8]\].

Methods {#Sec3}
=======

Participants {#Sec4}
------------

Ten right-handed (self-reported) healthy male volunteers (mean age ± standard deviation, 25 ± 4 years) participated in the study. All participants had no history of neurological and psychiatric disorders and were not taking any medications. The subjects underwent an fMRI with *N*-back task followed by a PET scan at rest, with the mean interval of 18.8 ± 20.6 days (mean ± standard deviation).

Radioligand preparation {#Sec5}
-----------------------

The \[^11^C\] TASP457 precursor and standard used in this study were provided by Taisho Pharmaceutical Co., Ltd. \[^11^C\] TASP457 was radiosynthesised by O-alkylation of the 2-pirydone-containing precursor (desmethyl TASP457) with \[^11^C\] methyl triflate \[[@CR4]\]. At a time of administration, the radiochemical purity of \[^11^C\] TASP457 was \> 95%, and its specific activity was \> 37 GBq/μmol.

PET procedures {#Sec6}
--------------

After intravenous injection of \[^11^C\] TASP457 (390 ± 6 MBq with molar activity of 92 ± 32 GBq/μmol), we acquired three-dimensional dynamic images with a PET camera (Eminence SET-3000GCT/X, Shimadzu, Kyoto, Japan) for 120 min in 39 frames of increasing duration (from 10 s to 5 min). All PET images were reconstructed using the filtered back-projection method (Gaussian filter, kernel 5 mm; the reconstructed in-plane resolution was 7.5 mm in full width at half maximum (FWHM); voxel size 2 × 2 × 2.6 mm) corrected for attenuation, randoms, scatter and head motion. Plasma input functions were measured with arterial blood sampling and metabolite analyses using a radio high-performance liquid chromatography, as described previously \[[@CR6]\].

fMRI procedures {#Sec7}
---------------

We designed a modified version of the *N*-back task used in a previous study \[[@CR2]\]. Participants responded to the numeric characters of previously seen stimuli according to three conditions, 0-, 1- and 2-backs.

A Siemens Verio 3 T MRI system (Siemens, Erlangen, Germany) was used to obtain T2\*-weighted echo-planar imaging (repetition time \[TR\] = 2000 ms, echo time \[TE\] = 25 ms, slice number = 33 (interleaved), slice thickness = 3.8 mm, matrixes = 64 × 64, 345 volumes) with bold oxygen level-dependent (BOLD) contrasts and structural T1 image (TR = 2300 ms, TE = 1.95 ms, slice number = 176, slice thickness = 1 mm, matrixes = 256 × 256).

Preprocessing analysis with SPM8 software (Wellcome Department of Cognitive Neurology, London, UK) included slice time correction, realignment, DARTEL normalisation and smoothing with a 6-mm FWHM Gaussian kernel. First-level analysis modelled the task as a block design, with working memory load as a linear regressor (0-back = − 1, 1-back = 0, 2-back = 1). Six realignment parameters and two derivatives were used as covariates. Artefacts in fMRI time series data were detected and corrected using robust weighted least squares \[[@CR9]\]. A mask image of the prefrontal cortex (including Brodmann areas 8, 9, 10, 11, 12, 13, 14, 24, 25, 32, 44, 45, 46 and 47) was created using WFU PickAtlas 3.0.5 software (Wake Forest University, Winston-Salem, NC). Group-level random effect analysis was performed to identify the activity corresponding to increased working memory load within the prefrontal cortex, using a threshold of *P* \< 0.001 (uncorrected) with a minimum cluster size of 20 voxels \[[@CR10]\]. Age was included as a nuisance covariate.

PET and fMRI analyses {#Sec8}
---------------------

The contrast coefficients (*ß* value) were extracted from the cluster images of increased working memory load. Time--activity curves were generated using data extracted from the PET images by applying the spherical (radius 4 mm) regions of interest images centred on the peak coordinates of each cluster. Total distribution volume (*V*~T~), which reflects the H~3~ receptor density in the brain, was calculated using Ichise's multilinear analysis (MA1) \[[@CR11]\] with the time--activity curves for the initial 60 min and plasma input functions according to the previous quantitative analysis of \[^11^C\] TASP457--PET data \[[@CR6]\]. The correlation analyses between MRI (*ß* value) and PET (*V*~T~) data were conducted with IBM SPSS Statistics, version 23 (IBM Corp., Armonk, NY). To compensate for the small sample size, we used a resampling procedure based on 5000 bootstrapped samples, using bias-correlated and accelerated (BCa) 95% confidence intervals (CIs) to estimate Pearson's correlation coefficient for the neural activity and *V*~T~.

Results {#Sec9}
=======

Behavioural data {#Sec10}
----------------

There were no significant differences in accuracy across the three *N*-back tasks (0-back, 98.0 ± 0.7%; 1-back, 98.1 ± 0.8; 2-back, 97.1 ± 1.1; Friedman test *P* = 0.66, *χ*^2^ = 0.84, df = 2). The performances of 1- and 2-backs showed the ceiling effects as they were not significantly different from the maximum accuracy of 100% (Wilcoxon signed-rank tests both *P*s \> 0.05, both *W*s = − 15); thus, the behavioural data were not used for further analyses to avoid spurious estimates.

Imaging data {#Sec11}
------------

Three clusters, in which neural activities assessed by fMRI were associated with increased working memory load, were detected in the bilateral DLPFC (the left middle frontal gyrus, left superior frontal gyrus and right middle frontal gyrus; Table [1](#Tab1){ref-type="table"}). Their *V*~T~ values (mL/cm^3^), estimated from PET data, were 7.4 ± 0.6 for the left middle frontal gyrus, 7.2 ± 0.9 for the left superior frontal gyrus and 7.0 ± 0.6 for the right middle frontal gyrus. The *ß* value of the right middle frontal gyrus (Fig. [1a](#Fig1){ref-type="fig"}) was negatively correlated with the *V*~T~ value of this region (Spearman *r* = − 0.65, *P* = 0.043, 95% BCa CI = (− 0.91, − 0.05), bias = 0.063, standard error = 0.21, Fig. [1b](#Fig1){ref-type="fig"}). No significant correlations were found in the other two clusters.Table 1Neural activity as a function of increased working memory loadRegionSideBACluster size*Z* value*xyz*Middle frontal gyrusLeft9833.91− 283234Superior frontal gyrusLeft8453.53− 26860Middle frontal gyrusRight8213.33281060(*x*, *y*, *z*) corresponds to Montreal Neurological Institute (MNI) coordinates*BA* Brodmann areaFig. 1**a** Group map showing the activity in the right middle frontal gyrus (red, *x*, *y*, *z* = 28, 10, 60) in response to increased working memory load. **b** The activity in the right middle frontal gyrus was negatively correlated with the H~3~ receptor radioligand retention (*V*~T~), which reflects the H~3~ receptor density. The dashed lines indicate 95% confidence intervals. The PET image on the graph indicates the distribution of the H~3~ receptors in the brain. The sagittal image was obtained by averaging parametric images of the 10 subjects. The parametric images were calculated using Ichise's multilinear analysis to estimate total distribution volume for each voxel and spatially normalised thereafter. The circle indicates the location of the activated region detected in fMRI during performing working memory task in the right middle frontal gyrus shown in **a**

Discussion {#Sec12}
==========

The present study revealed that higher activity in the right DLPFC due to increased working memory load, which was consistent with the findings of previous studies \[[@CR1], [@CR2]\], was associated with lower density of H~3~ receptors. Preclinical studies demonstrated that H~3~ receptor blockade with H~3~ antagonists increased the release of neurotransmitters such as acetylcholine and dopamine, resulting in enhanced cognition, whereas H~3~ agonists impaired cognition \[[@CR3]\]. Enhanced cognition has also been reported in H~3~ receptor knockout rodents \[[@CR3]\]. Thus, the individual variability of H~3~ receptor density may reflect the ability of neurotransmitter release. Taken together with our findings, these results indicate that inhibition of H~3~ receptors, which increases the release of histamine and other neurotransmitters, plays a role in working memory activation in the right DLPFC.

Although very few studies have investigated the role of H~3~ receptors in working memory in humans, one fMRI study revealed that an increase in histamine neurotransmission induced by betahistine (H~3~ antagonist/H~1~ agonist) moderately increased right DLPFC activity during *N*-back task performance \[[@CR12]\]. This finding also supports the role of the H~3~ receptor inhibition in DLPFC activation, consistent with our study results.

One of the key limitations of this study is its small sample size, which decreased its statistical power. Moreover, we were unable to establish a causal relationship between H~3~ receptor density and working memory activity in the DLPFC or to examine the association between H~3~ receptors and working memory performance. Further studies with a larger sample size and the use of H~3~ agonists/antagonists are required to establish the causal relationship between H~3~ receptors and working memory activity and its performance.

Conclusion {#Sec13}
==========

In conclusion, the present study showed for the first time that H~3~ receptor density was associated with working memory activity in the right DLPFC in humans, revealing a histaminergic mechanism underlying working memory. This finding supports the potential of histaminergic modulators, especially those that affect H~3~ receptors, for treating cognitive impairments in neuropsychiatric disorders.
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